## WHAT IS CLAIMED IS:

	1.	An	isolated polynucleotide comprising:
		a)	a nucleotide sequence encoding a polypeptide
5			comprising the amino acid sequence of SEQ ID
			NO:2;
		b)	a nucleotide sequence encoding a polypeptide
			comprising amino acid residues 72-93, 147-162,
			191-211 OR 217-238 of SEQ ID NO:2;
		C)	a nucleotide sequence encoding a polypeptide
10			comprising the amino acid sequence of SEQ ID
			NO:4;
		d)	a nucleotide sequence encoding a polypeptide
			comprising amino acid residues 55-76, 132-150,
			177-199 or 213-234 of SEQ ID NO:4;
		e)	a nucleotide sequence encoding a polypeptide
15			comprising the amino acid sequence of SEQ ID
			NO:6;
		f)	a nucleotide sequence encoding a polypeptide
			comprising amino acid residues 47-68, 123-138,
			167-187 or 193-214 of \SEQ ID NO:6;
••		g)	a nucleotide sequence encoding a polypeptide
20			comprising the amino acid sequence of SEQ ID
		<b>b</b> \	NO:8;
		h)	a nucleotide sequence endoding a polypeptide
			comprising amino acid residues 46-67, 122-140,
		i)	166-187 or 194-213 of SEQ TD NO:8;
25		-,	a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID
25			NO:9;
		j)	a nucleotide sequence encoding a polypeptide
		<i>3</i> /	comprising amino acid residues 77-98, 153-167,
			197-217 or 223-242 of SEQ ID No:9;
		k)	nucleotides 232-1599, 445-513, 670-717, 802-
30		•	864 or 880-945 of the nucleotide sequence of
			SEQ ID NO:1;

5

15

20

30

- 1) nucleotides 83-1669, 245-310, 476-532, 611-679 or 719-784 of the nucleotide sequence of SEQ ID NO:3;
- m) nucleotides 247-1530, 385-450, 613-660, 745-807 or 823-888 of the nucleotide sequence of SEQ ID NO:5; or
- n) nucleotides 205-1599, 340-395, 568-624, 700-765 or 784-843 of the nucleotide sequence of SEQ ID No:7.
- 2. An isolated polynucleotide which hybridizes to the complement of the polynucleotide of Claim 1 under stringent hybridization conditions.
  - 3. An isolated polynucleotide which comprises the complement of the polynucleotide of Claim 1.

4. A vector comprising the isolated polynucleotide of Claim 1 or 2.

5. An expression vector comprising the isolated polynucleotide of Claim 1 or 2.

6. A host cell genetically engineered to contain the polynucleotide of Claim 1 or 2.

7. A host cell genetically engineered to contain the polynucleotide of Claim 1 or 2 in operative association with 25 a regulatory sequence that controls expression of the polynucleotide in the host cell.

- 8. An isolated polypeptide comprising:
  - a) the amino acid sequence of SEQ ID NO:2;
  - b) amino acid residues 72-93, 147-162, 191-211 OR 217-238 of SEQ ID NO:2;
  - c) the amino acid sequence of SEQ ID NO:4;
  - d) amino acid residues 55-76, 132-150 177-199 or 213-234 of SEQ ID NO:4;

-108-

- e) the amino acid sequence of SEQ ID NO:6;
- f) amino acid residues 47-68, 123-138, 167-187 or 193-214 of SEQ ID NO:6;
- g) the amino acid sequence of SEQ ID NO:8;
- 5 h) amino acid residues 46-67, 122-140, 166-187 or 194-213 of SEQ ID NO:8;
  - i) the amino acid sequence of SEQ ID NO:9; or
  - j) amino acid residues 77-98, 153-167, 197-217 or 223-242 of SEQ ID NO:9;
- 9. A composition comprising the polypeptide of Claim 8 and a carrier.
  - 10. An antibody directed against the polypeptide of Claim 8.
- 15 11. A method for detecting a polynucleotide of Claim 1 or 2 in a sample, comprising:
  - a) contacting the sample with a compound that binds to and forms a complex with the polynucleotide for a period sufficient to form the complex; and
- b) detecting the complex, so that if a complex is detected, a polynucleotide of Claim 1 or 2 is detected.
  - 12. A method for detecting a polynucleotide of Claim 1 or 2 in a sample, comprising:
- a) contacting the sample under stringent hybridization conditions with nucleic acid primers that anneal to a polynucleotide of Claim 1 or 2 under such conditions; and
- b) amplifying the annealed polynucleotides, so that if a polynucleotide is amplified, a polynucleotide of 30 Claim 1 or 2 is detected.
  - 13. The method of Claim 12, wherein the polynucleotide is an RNA molecule that encodes a polypeptide of Claim 8, and



A DOCPHOENIX

APPL PARTS	NPL	CTNF
AITETARTO	Non-Patent Literature	Count Non-Final
IMIS	OATH	CTRS
Internal Misc. Paper	Oath or Declaration	Count Restriction
LET Misc. Incoming Letter	PET	EXIN
	Petition	Examiner Interview
371P	RETMAIL Mail Returned by USPS	M903
	SEQLIST	M905
AAmendment Including Elections	Sequence Listing	DO/EO Missing Requirement
ABST	SPEC	NFDR
Abstract	Specification SPEC	Formal Drawing Required
ADS	SPEC NO	NOA
Application Data Sheet	Specification Not in English	Notice of Allowance
AF/D	TRNA	PETDEC
Affidavit or Exhibit Received	Transmittal New Application	Petition Decision
APPENDIXAPPENDIX		
, ,		
ARTIFACT	OUTGOING	INCOMING
BIB	CTMS	AP.B
Bib Data Sheet	Misc. Office Action	Appeal Brief
CLM	1449	C.AD
Claim	Signed 1449	Change of Address
COMPUTER	892	N/AP
Computer Program Listing	892	Notice of Appeal
CRFL	ABN	PA
All CRF Papers for Backfile		Change in Power of Attorney
DIST	APDEC	REM
Terminal Disclaimer Filed	Board of Appeals Decision	Applicant Remarks in Amendment
Drawings DRW	APEA Examiner Answer	XT/_ Extension of Time filed separate
FOR	CTAV	Extension of fillie filed separate
Foreign Reference	Count Advisory Action	
FRPR	CTEQ	
Foreign Priority Papers	Count Ex parte Quayle	
IDS	CTFR	File Wrapper
IDS Including 1449	Count Final Rejection	i ne wiappei
	ECBOX	EN/CLAA
Internal	Evidence Copy Box Identification	FWCLM
SRNT	WCLM	IIFW
Examiner Search Notes	Claim Worksheet	File Wrapper Issue Information
CLMPTO	WFEE	SRFW
PTO Prepared Complete Claim Set	Fee Worksheet	File Wrapper Search Info

## ABSTRACT OF THE INVENTION

The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins. In particular, the polypeptides and polynucleotides of the invention comprise amino acid and nucleic acid sequences of novel CD39-like gene and gene products.